Biomedical Engineering Reference
In-Depth Information
183. Gendelman, M.; Halligan, N.; Komorowski, R.; Logan, B.; Murphy, W. J.; Blazar, B. R., et al.
Alpha Phenyl-tert-butyl nitrone (PBN) Protects Syngeneic Marrow Transplant Recipients
from the Lethal Cytokine Syndrome Occurring After Agonistic CD40 Antibody Administra-
tion.
Blood
2005,
105,
428-431.
184. Hixon, J. A.; Anver, M. R.; Blazar, B. R.; Panoskaltsis-Mortari, A.; Wiltrout, R. H.;
Murphy, W. J. Administration of Either anti-CD40 or Interleukin- 12 Following Lethal Total
Body Irradiation Induces Acute Lethal Toxicity Affecting the Gut.
Biol. Blood Marrow Trans-
plant
2002,
8,
316-325.
185. Bartholdy, C.; Kauffmann, S. O.; Christensen, J. P.; Thomsen, A. R. Agonistic Anti-CD40
Antibody Profoundly Suppresses the Immune Response to Infection with Lymphocytic Cho-
riomeningitis Virus.
J. Immunol.
2007,
178,
1662-1670.
186. Lonsdorf, A. S.; Kuekrek, H.; Stern, B. V.; Boehm, B. O.; Lehmann, P. V.; Tary-Lehmann, M.
Intratumor CpG-oligodeoxynucleotide Injection Induces Protective Antitumor T cell Immu-
nity.
J. Immunol.
2003,
171,
3941-3946.
187. Baines, J.; Celis, E. Immune-mediated Tumor Regression Induced by CpG-Containing Oligo-
deoxynucleotides.
Clin. Cancer Res.
2003,
9,
2693-2700.
188. Scarlett, U. K.; Cubillos-Ruiz, J. R.; Nesbeth, Y. C.; M, D. G.; Engle, X.; Gewirtz, A. T., et al.
In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-infiltrating
Dendritic Cells from Immunosuppressive to Immunostimulatory Cells.
Cancer Res.
2009,
69,
7329-7337.
189. Stone, G. W.; Barzee, S.; Snarsky, V.; Santucci, C.; Tran, B.; Langer, R., et al. Nanoparticle-
delivered Multimeric Soluble CD40L DNA Combined with Toll-Like Receptor Agonists as a
Treatment for Melanoma.
PLoS One
2009,
4,
e7334.
190. Wingender, G.; Garbi, N.; Schumak, B.; Jungerkes, F.; Endl, E.; von Bubnoff, D., et al. Sys-
temic Application of CpG-rich DNA Suppresses Adaptive T Cell Immunity Via Induction of
IDO.
Eur. J. Immunol.
2006,
36,
12-20.
191. Mellor, A. L.; Baban, B.; Chandler, P. R.; Manlapat, A.; Kahler, D. J.; Munn, D. H. Cutting
Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indole-
amine 2,3-dioxygenase-dependent T Cell Regulatory Functions Via IFN Type 1 Signaling.
J.
Immunol.
2005,
175,
5601-5605.
192. Heikenwalder, M.; Polymenidou, M.; Junt, T.; Sigurdson, C.; Wagner, H.; Akira, S., et al.
Lymphoid Follicle Destruction and Immunosuppression After Repeated CpG Oligodeoxy-
nucleotide Administration.
Nat. Med.
2004,
10,
187-192.
193. Gimbel, M. I.; Delman, K. A.; Zager, J. S. Therapy for Unresectable Recurrent and In-Transit
Extremity Melanoma.
Cancer Control
2008,
15,
225-232.
194. Den Otter, W.; Jacobs, J. J.; Battermann, J. J.; Hordijk, G. J.; Krastev, Z.; Moiseeva, E. V., et al.
Local Therapy of Cancer with Free IL-2.
Cancer Immunol. Immunother.
2008,
57,
931-950.
195. Heckelsmiller, K.; Rall, K.; Beck, S.; Schlamp, A.; Seiderer, J.; Jahrsdorfer, B., et al. Peri-
tumoral CpG DNA Elicits a Coordinated Response of CD8 T Cells and Innate Effectors
to Cure Established Tumors in a Murine Colon Carcinoma Model.
J. Immunol.
2002,
169,
3892-3899.
196. Johnson, E. E.; Lum, H. D.; Rakhmilevich, A. L.; Schmidt, B. E.; Furlong, M.; Buhtoiarov, I. N.,
et al. Intratumoral Immunocytokine Treatment Results in Enhanced Antitumor Effects.
Cancer
Immunol. Immunother.
2008,
57,
1891-1902.
197. Simmons, A. D.; Moskalenko, M.; Creson, J.; Fang, J.; Yi, S.; Van roey, M. J., et al. Local
Secretion of Anti-CTLA-4 Enhances the Therapeutic Efficacy of a Cancer Immunotherapy
with Reduced Evidence of Systemic Autoimmunity.
Cancer Immunol. Immunother.
2008,
57,
1263-1270.
